carmine zoccali - nefroloji.org.tr ekİm... · normal (sham) uninephrectomy fibrosis (%) 5.0 2.5...
TRANSCRIPT
CKD as a systemic diseaseCarmine Zoccali
The brain as a systems master : links with
the heart, the kidney and the bone and the
inter-organs cross-talks (Heart/vessels –
Kidney and Bone-Kidney)
Systems Physiology
The CKD phenotype as a systemic disease:
kidney dysfunction as a trigger of multi-organs
disturbances
Arthur C. Guyton
Pressure
Natriuresis
0 10 30 1 2 4 8 16 32 1 2 4 8 16 1 2 4 8 16
Time after sudden change in Pressure
(like in acute HF)
12
9
6
3
0
sec min hours days
Arthur C. Guyton
BP deviation 80%
Residual BP deviation after
full activation of the
counter-regulatory system
11.5 %
7
! Infinite
gain
Baroreceptor,
Chemoreceptors Ischemic
CNS response
BP deviation 80%____
Residual BP deviation after
full activation of Pressure
Natriuresis 0%
Pressure
Natriuresis
0 10 30 1 2 4 8 16 32 1 2 4 8 16 1 2 4 8 16
Time after sudden change in Pressure
12
9
6
3
0
sec min hours days
Di Bona GF Sawin L Renal nerve activity
in conscious rats during volume expansion
and depletion. Am J Physiol 1985 Jan;248(1
Pt 2):F15-23
Renal Nerve Activity
(Units)
100
80
60
40
20
0
Baseline Isotonic saline
load
- 44%
Arthur C. Guyton
Geoffrey F. Di Bona
12
9
6
3
0
NO
1993;22:535-541
ADMANO NO
NorepinephrineBaldock PA et al., Neuropeptide Y Knockout Mice Reveal a Central Role of
NPY in the Coordination of Bone Mass to Body Weight. PlosOne 4(12):
e8415.
Wild type NPY-/-(knock-out)
NPY receptors
OSTEOBLASTS
Neuropeptide Y
osteoblast acitivity
(alkaline phosphatase)
Representative micro-computed
tomographs of the distal femoral
metaphysis
Neural
Synapsis
Normal NPY
levelsUnmeasurable
NPY levels
Klotho
FGF23
CC
CC(F)GF-R
FGF23
FGF23
FGF23
FGF23
FGF23
Myocardiocyte
Kl +/ -
Integrity of the
whole receptor
assembly is
needed for
renal effects
(Phosphaturia,
1,25 vit D)PO4=
Ca++
PTH
1,25 VD
FGF23
Klotho
PO4=Inhibition of the Na-
dependent phosphate
cotransporter
Faul C and Wolf M
2011;121(11):4393–4408
Mineral Metabolism
The brain as a systems master : links with
the heart, the kidney and the bone and the
inter-organs connections (Heart/vessels –
Kidney and Bone-Kidney)
Systems Physiology
The CKD phenotype as a systemic disease:
kidney dysfunction as a trigger of multi-organs
disturbances
restraint of central
sympathetic activity
Sympathetic fibers,
peroneal nerve
afferent
nerves
Control
subjects
Patients
with CKDWith ACE
inhibitors
Neuropeptide YZoccali C, Mallamaci F, unpublished
(pmol/L)
3002001000
24h Proteinuria (g/day)3.0
2.5
2.0
1.5
1.0
.5
0.0
(pmol/L)
3002001000
GFR cys-creat (ml/min/1.73m2)160
140
120
100
80
60
40
20
0
Wild NPY -/-
AJKD 2007 ;50:1001-8
NPY receptors
Neuropeptide Y
osteoblast acitivity
(alkaline phosphatase)
Brain-Bone connection
Normal
(sham)Uninephrectomy
Fibrosis (%)
5.0
2.5
0.0
Martin FL, et al. Am J Physiol Regul
Integr Comp Physiol. Jan 15, 2012; 302(2):
R292–R299.
Changes in the
activity of 103 genes
in the TGFβ and
apoptosis pathways
Stage 1-2 CKD model…. Unchanged renin,
aldosterone and BP….
... Well beyond the Sympathetic
System, renal function loss has
unsuspected adverse effects on
the heart
1.51.00.50.0-0.5-1.0
120
100
80
60
40
20
LVMI(g/m2.7)
ADMA (lg10 mol/L)
Zoccali C et al. Kidney International 2002;62:339-45.
21:444, 2010
12
9
6
3
0
ADMALVH
NO myocardial growth
restraint
Mihout, F et al., J Pathol 223:37, 2011
Uninephrectomized
mice
continous infusion of
ADMA by mini-pumps
TGF
12
9
6
3
0
ADMALVH
NO myocardial growth
restraint
Fully preventable by
reducing ADMA levels
1.0
0.75
0.50
0.25
ESRD risk Death risk
0 10 20 30 0 10 20 30 months
ADMA < 0.76 µM/L
ADMA >= 0.76 µM/L
HR 2.20 (95% CI 1.20, 4.04)
Ravani P, Tripepi G, Malberti F, Testa F, Mallamaci F, Zoccali. JASN 16: 2449, 2005
Few today doubt that high ADMA is a
relevant cardiovascular and renal risk
factor but numerous attempts at
advancing drugs stimulating ADMA
degradation in CKD patients have
failed to enter phase 1-2 studies.
12
9
6
3
0
ADMA
Klotho
CC
CC(F)GF-R
FGF23 ADMA
r= - 0.48
P<0.001
r= - 0.21
P<0.001
Competitive Interaction
P =0.001
P for effect modification=0.009
100806040200
3.5
3.0
2.5
2.0
1.5
1.0
0.5
eGFR (ml/min/1.73m2)
lg10 pg/mL
100806040200
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
eGFR (ml/min/1.73m2)
(µMol/L)
ADMA
FGF23
HR (20 pg/ml)
0.450.30 0.60 0.75 0.90 1.05 1.20
1.24
1.20
1.16
1.12
1.08
1.04
1.00
0.96
0.92
0.88
ADMA (µMol/L)
FGF23
HR (20 pg/ml FGF-23)
0.450.30 0.60 0.75 0.90 1.05 1.20
1.24
1.20
1.16
1.12
1.08
1.04
1.00
0.96
0.92
0.88
ADMA (µMol/L)
FGF23
Southern Italy cohort, n=756, Tripepi G, Mallamaci F Zoccali C JASN 2015
MMKD Central-Northern European cohort,
n=176 Florian Kronenberg (Fliser, Ritz)
A quintessential example of the
systemic , widespread nature of the
risk phenotype of CKD.
FGF23, a bone factor and
ADMA, an endothelium
substance, interact in CKD
progression.
Renin
Blood Volume nor. or
Salt intake
Cardio Vascular
Disease
Blood Volume
Salt intake Continuous
fluids loss
Survival
Death
….a «reductionist -Cartesian- approach»
deliberately adopted for clarity and communication….
..BUT EFFECTS ARE «CONTEXT DEPENDENT»
..a methodological critique and self-
critique…..
Exactly the same happens
with ADMA, which may be
life saving in the setting of
septic shock.
1° day of observation
n…day of observation
we explore connections with the reductionist
approach and identify syndromes that do
not exists
Kidney International Supplements (2011) 1, 2–5;
Metabolomics and Metebonomics move the
risk profile of CKD from mono-dimensionality to
multi-dimensionality.
HPLC- mass spectrometry
and NMR Spectroscopy
Understanding the complexity will allow
precise individual risk profiling and treatment
Summary and Conclusions
Inter-organs connections and integration during growth, adult life and
aging is the most complex biological process in living organisms
Until now this process has been mainly investigated with a reductionist
approach.
CKD profoundly perturbs inter-organs relationships. We currently identify
pseudo-syndromes. We have just a glimpse into this complex scenario.
A mature technology for a system-analysis approach to physiology and
pathophysiology exists. A novel approach based on this technology has
already started to form a new basis for clinical research and clinical
epidemiology.